A review of glioblastoma immunotherapy

ConclusionsCurrent clinical trials are exploring combination therapy and novel treatment strategies beyond immune checkpoint therapies and vaccine therapy such as CAR T cells. There is also an effort to establish synergy between immunotherapy and current standard of care. Furthermore, recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific GBM treatment.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Immune-checkpoint inhibitors (ICIs) represented by programmed death receptor inhibitors (PD-1), programmed death receptor ligand inhibitors (PD-L1) and cytotoxic-T-lymphocytes antigen 4 inhibitors (CTLA-4), drastically changed the management of several neoplastic diseases, including metastatic non-small-cell lung cancer (NSCLC), melanoma, and metastatic renal cell carcinoma (RCC).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Immunotherapy enhances a patient's own immune system to fight against malignancy and has become increasingly popular during the last decade. Tumor cells can escape destruction by the patient's immune system by overexpression of immunosuppressive molecules such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1) receptor, and its ligand PD-L1. Immunotherapy agents target these inhibitors and basically reactivate the cytotoxic lymphocytes to destroy the tumor cells. Immunotherapy agents currently are FDA-approved for advanced malignancies including melanoma, Hodgkin lymphoma, head and neck...
Source: Contemporary Diagnostic Radiology - Category: Radiology Tags: ARTICLE Source Type: research
ConclusionsWe find sufficient cause to suggest that the predictive clinical value of TMB should not be overstated or oversimplified. While it is readily quantified, TMB is at best a limited surrogate biomarker of immunotherapy response. The data do not support isolated use of TMB in renal cell carcinoma.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
Conclusions: Sebaceous carcinoma currently has few effective adjuvant treatment options. The expression of PD-1, PD-L1, and PD-L2 on infiltrating immune cells and PD-L2 on tumor cells restrains T-cells from full activation and proliferation, therefore limiting the antitumor effect of T-cells, tipping the balance toward unopposed tumor progression. Consequently, PD-1 or PD-L1 inhibitors may have a role in sebaceous carcinoma treatment. Given the prevalence of PD-L2 expression in sebaceous carcinoma and the lack of PD-L2 blockade therapy available, PD-1 blockade may provide benefit over PD-L1 inhibitors. PD-1 blockade in c...
Source: Ophthalmic Plastic and Reconstructive Surgery - Category: Opthalmology Tags: Original Investigations Source Type: research
DiscussionThe POPCORN study provides a unique platform for translational research to determine the mechanism of action of a novel proposed combination immunotherapy for cancer.Trial registrationProspectively registered on Australian New Zealand Clinical Trials Registry (ACTRN12618001121257) on 06/07/2018.
Source: Trials - Category: Research Source Type: clinical trials
Nivolumab is a fully human, immunoglobulin G4 (kappa) isotype monoclonal antibody that binds programmed cell death protein 1 (PD-1) on activated immune cells and disrupts the engagement of the receptor with its ligands programmed death-ligand 1 (PD-L1: B7-H1/CD274 and PD-L2: B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the antitumor response of the host [1]. In previous clinical trials, nivolumab has shown activity in several tumor types, including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), hodgkin lymphoma, and malignant pleural mesothelioma.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Introduction: The prognosis for recurrent intrahepatic cholangiocarcinoma with bone metastasis remains dismal and its treatment poses a challenge for oncologists. To date, only 2 cases were reported in which pembrolizumab, an agent against programmed cell death protein-1 (PD-1), combined with chemotherapy led to a complete response.[1] The safety and efficacy of nivolumab-based immunotherapy combined with lenvatinibin intrahepatic cholangiocarcinoma is unknown. Patient concerns: A 40-year-old female was identified as having a lesion of 7.0 cm in diameter in the right lobe of the liver. In addition, calculi in the ma...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Publication date: Available online 28 October 2019Source: Journal of Geriatric OncologyAuthor(s): Andrea Sbrana, Rachele Antognoli, Giuseppe Pasqualetti, Giuseppe Linsalata, Chukwma Okoye, Valeria Calsolaro, Federico Paolieri, Francesco Bloise, Sergio Ricci, Andrea Antonuzzo, Fabio MonzaniAbstractBackgroundOlder adults with cancer are less likely to be offered treatment for cost-benefit concern. The Multi-Prognostic Index (MPI) has been validated in various clinical settings for survival estimation. We aimed to evaluate MPI as a screening tool for older adults with cancer eligible to receive immunotherapy.Patients and Meth...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsWe review the literature on pericardial effusion under nivolumab to further discuss the hallmarks of pericardial effusion under nivolumab and the management of nivolumab therapy in this situation. In conclusion, pericardial effusion as an immune-related adverse event under nivolumab appears less rare than initially thought and may require particular attention.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsThe RP2D of rSIFN-co was 30ug (1.6  × 107IU) 3x/week for 21days followed by 7 days ’ rest. Anti-tumour activity seen in heavily pre-treated advanced solid tumor patients. especially in HCC. Future plans involve combinations with other immunotherapies.Clinical trial identificationNCT02387307.Legal entity responsible for the studySichuan Huiyang Life Science and Technology Corporation.FundingSichuan Huiyang Life Science and Technology Corporation.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Chemotherapy | Clinical Trials | Environmental Health | Immunotherapy | Kidney Cancer | Lung Cancer | Melanoma | Neurology | Non-Small Cell Lung Cancer | Radiation Therapy | Renal Cell Carcinoma | Skin Cancer | Vaccines